Literature DB >> 9229019

Synthetic polypeptides corresponding to the non-repeat regions from the circumsporozoite protein of Plasmodium falciparum: recognition by human T-cells and immunogenicity in owl monkeys.

J A López1, J M González, A Kettner, M Arévalo-Herrera, S Herrera, G Corradin, M A Roggero.   

Abstract

Synthetic polypeptides encompassing the non-repeated regions of the circumsporozoite protein (CSP) of Plasmodium falciparum are very immunogenic in mice and are recognized by sera from donors living in regions where malaria is endemic, both in Africa and South America. Long polypeptides, encompassing the N- or C-terminal regions, have now been used to demonstrate peptide-specific T cells in donors living in an endemic area of Colombia. Although the N-terminal peptide (22-125) was recognized almost exclusively by donors from the endemic area, the patterns of recognition of the C-terminal peptide (289-390) in donors from endemic and non-endemic areas were similar and like the pattern with smaller peptides. The availability of the long polypeptides made it possible to compare T-cell responses to the non-repeated regions of the CSP with the presence of peptide-specific antibodies. No correlation was found and no antibodies were detected in donors from non-endemic regions. The long polypeptides also elicited strong antibody and T-cell responses in owl monkeys (Aotus lemurinus). The antibodies generated against the synthetic peptides in such monkeys also recognized sporozoites, the natural infective form of the parasite. The results emphasise the potential of the peptides tested as malaria-vaccine candidates. Not only are they recognized by humans at both the B- and T-cell level but they also elicit strong responses in monkeys and encompass several distinct T-cell epitopes, thus overcoming the limitations of specific, major-histocompatibility-complex restriction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9229019

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  7 in total

1.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 2.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

3.  Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity.

Authors:  M Theisen; D Dodoo; A Toure-Balde; S Soe; G Corradin; K K Koram; J A Kurtzhals; L Hviid; T Theander; B Akanmori; M Ndiaye; P Druilhe
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

4.  Malaria epidemiology in low-endemicity areas of the northern coast of Ecuador: high prevalence of asymptomatic infections.

Authors:  Fabián E Sáenz; Andrea Arévalo-Cortés; Gabriela Valenzuela; Andrés F Vallejo; Angélica Castellanos; Andrea C Poveda-Loayza; Juan B Gutierrez; Alvaro Alvarez; Yi Heng Yan; Yoldy Benavides; Luis Enrique Castro; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Malar J       Date:  2017-07-26       Impact factor: 2.979

5.  The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.

Authors:  Régine Audran; Floriana Lurati-Ruiz; Blaise Genton; Hildur E Blythman; Opokua Ofori-Anyinam; Christophe Reymond; Giampietro Corradin; François Spertini
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

6.  Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso.

Authors:  I Nebie; A Diarra; A Ouedraogo; A B Tiono; A T Konate; A Gansane; I Soulama; S Cousens; O Leroy; S B Sirima
Journal:  Parasite Immunol       Date:  2009-08       Impact factor: 2.280

7.  First characterization of Plasmodium vivax liver stage antigen (PvLSA) using synthetic peptides.

Authors:  Youn-Kyoung Goo; Eun-Jeong Seo; Yeon-Kyung Choi; Hyun-Il Shin; Jetsumon Sattabongkot; So-Young Ji; Chom-Kyu Chong; Shin-Hyung Cho; Won-Ja Lee; Jung-Yeon Kim
Journal:  Parasit Vectors       Date:  2014-02-12       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.